Niacin (tablet): Difference between revisions

Niacin (tablet)
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

← Older edit Newer edit →

VisualWikitext

Revision as of 17:54, 4 May 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Niacin (tablet) is a {{{drugClass}}} that is FDA approved for the treatment of {{{indication}}}. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.

NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.

NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate.

In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction.

In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease.

NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia.

Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1

Developed by:

Class of Recommendation:

Strength of Evidence:

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Niacin (tablet) in adult patients.

Non–Guideline-Supported Use

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Niacin (tablet) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Niacin (tablet) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1

Developed by:

Class of Recommendation:

Strength of Evidence:

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Niacin (tablet) in pediatric patients.

Non–Guideline-Supported Use

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Niacin (tablet) in pediatric patients.

Contraindications

Condition1

Warnings

Description

Precautions

Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Niacin (tablet) in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Niacin (tablet) in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Drug Interactions

Drug

Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Niacin (tablet) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Niacin (tablet) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Niacin (tablet) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Niacin (tablet) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Niacin (tablet) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Niacin (tablet) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Niacin (tablet) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Niacin (tablet) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Niacin (tablet) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Niacin (tablet) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Niacin (tablet) in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Intravenous

Monitoring

There is limited information regarding Monitoring of Niacin (tablet) in the drug label.

Description

IV Compatibility

There is limited information regarding IV Compatibility of Niacin (tablet) in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

Description

Management

Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Niacin (tablet) in the drug label.

Pharmacology

There is limited information regarding Niacin (tablet) Pharmacology in the drug label.

Mechanism of Action

Structure

File:Niacin (tablet)01.png

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Niacin (tablet) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Niacin (tablet) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Niacin (tablet) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Niacin (tablet) in the drug label.

How Supplied

Storage

There is limited information regarding Niacin (tablet) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Niacin (tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Niacin (tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Niacin (tablet) in the drug label.

Precautions with Alcohol

Alcohol-Niacin (tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

®^[1]

Look-Alike Drug Names

A® — B®^[2]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ Empty citation (help)
↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Niacin (tablet)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Niacin (tablet)
 |Label Name=Niacin (tablet)11.png

}}

{{#subobject:

 |Label Page=Niacin (tablet)
 |Label Name=Niacin (tablet)11.png

}}

[1] Empty citation (help)

[www.ismp.org-2] "http://www.ismp.org". External link in |title= (help)

[1]

[2]

@@ Line 1: / Line 1: @@
 {{DrugProjectFormSinglePage
+|authorTag={{KS}}
 |aOrAn=a
 |indicationType=treatment
-|hasBlackBoxWarning=Yes
 |adverseReactions=<!--Black Box Warning-->
 |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
@@ Line 12: / Line 12: @@
 <!--FDA-Labeled Indications and Dosage (Adult)-->
-|fdaLIADAdult======Condition1=====
+|fdaLIADAdult===Indications==
-* Dosing Information
+* Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.
-:* Dosage
+* NIASPAN is indicated to reduce elevated [[TC]], [[LDL-C]], [[Apo B]] and [[TG]] levels, and to increase HDL-C in patients with primary [[hyperlipidemia]] and mixed [[dyslipidemia]].
-=====Condition2=====
+* NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary [[hyperlipidemia]] and mixed [[dyslipidemia]] when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate.
-* Dosing Information
+* In patients with a history of [[myocardial infarction]] and [[hyperlipidemia]], niacin is indicated to reduce the risk of recurrent nonfatal [[myocardial infarction]].
-:* Dosage
+* In patients with a history of [[coronary artery disease]] ([[CAD]]) and [[hyperlipidemia]], niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of [[atherosclerotic disease]].
-=====Condition3=====
+* NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated [[TC]] and LDL-C levels in adult patients with primary [[hyperlipidemia]].
-* Dosing Information
+* Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe [[hypertriglyceridemia]] who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.
-:* Dosage
-=====Condition4=====
-* Dosing Information
-:* Dosage
-<!--Off-Label Use and Dosage (Adult)-->
-<!--Guideline-Supported Use (Adult)-->
 |offLabelAdultGuideSupport======Condition1=====